Akari Therapeutics (AKTX) Cash from Financing Activities (2014 - 2026)
Akari Therapeutics (AKTX) posted quarterly Cash from Financing Activities of $53000.0 for Q1 2026, down 97.52% year-on-year from $2.1 million in Q1 2025, and down 99.08% on a QoQ basis from $5.8 million in Q4 2025.
Akari Therapeutics (AKTX) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Cash from Financing Activities for 8 consecutive years, with $53000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities fell 97.52% year-over-year to $53000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (down 4.45% YoY) and the FY2025 annual result came in at $13.2 million, up 19.87% from the prior year.
- Cash from Financing Activities declined to $53000.0 in Q1 2026 per AKTX's latest filing, from $5.8 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for AKTX reached as high as $7.8 million in Q2 2024 and fell as low as -$443000.0 in Q3 2024.
- A 4-year average of $2.6 million and a median of $2.1 million in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 2567.7% — and 2026, when it plunged 97.52%.
- Year by year, Cash from Financing Activities stood at $3.5 million in 2023, then sank by 38.75% to $2.2 million in 2024, then soared by 167.41% to $5.8 million in 2025, then slumped by 99.08% to $53000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $53000.0, $5.8 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - | 53,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53,000.00 |
| Mar 31, 2026 | 53,000.00 |
| Dec 31, 2025 | 5.76 Mn |
| Dec 31, 2025 | 5.76 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Sep 30, 2024 | -443,000.00 |
| Sep 30, 2024 | -443,000.00 |
| Jun 30, 2024 | 7.76 Mn |
| Jun 30, 2024 | 7.76 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 3.52 Mn |
| Dec 31, 2023 | 3.52 Mn |